NHLBI Announces Participation in PA-18-932 "Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)"

Notice Number: NOT-HL-19-719

Key Dates
Release Date: September 4, 2019

Related Announcements

Issued by
National Heart, Lung, and Blood Institute (NHLBI)


The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-18-932 "Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)".

The following sections of PA-18-932 have been modified (shown in italics):

Part 1. Overview Information

Components of Participating Organizations

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The NIH Office above may co-fund applications assigned to those Institutes/Centers.

National Cancer Institute (NCI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute on Drug Abuse (NIDA)

National Institute of Mental Health (NIMH)

National Institute on Minority Health and Health Disparities (NIMHD)

National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.121; 93.242; 93.273; 93.279; 93.307; 93.399; 93.866, 93.837, 93.838, 93.839, 93.849, 93.233

Section I. Funding Opportunity Description

The National Heart, Lung, and Blood institute (NHLBI) provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, blood, and sleep (HLBS) diseases. As such, the NHLBI seeks research proposals that would produce generalizable new knowledge informing screening strategies in high-burden and underserved communities and populations, to reduce disparities in screening. Grant applications should address conditions for which there is already good evidence of benefit from screening at least in some demographic or clinical subgroups. Applications could address screening for conditions where the supportive evidence is considered insufficient by the US Preventative Services Task Force (USPSTF), such as atrial fibrillation and obstructive sleep apnea, but for which screening is recommended by at least one major organization, such as the American Heart Association (AHA), American College of Cardiology (ACC), the American College of Physicians (ACP), and the American Academy of Sleep Medicine (AASM). Variation in clinical screening practice guideline recommendations for HBLS conditions such as atrial fibrillation, abdominal aortic aneurysm, and obstructive sleep apnea calls for strengthening the evidence base for prevention screening modalities. NHLBI is interested in supporting applications that also focus on high-risk and underserved/under screened clinical and demographic subgroups where the likelihood of benefit from screening is stronger (e.g., atrial fibrillation in rural populations, older persons, and those with hypertension or diabetes; hypertension in younger persons and men; and obstructive sleep apnea in morbidly obese persons). Proposed screening strategies should have potential to be scalable, sustainable, and affordable.

Examples of responsive proposals include the following:

  • Analyze or test the impact of a streamlined personalized screening for competing risks/common risk factors, including hypertension, diabetes, and obstructive sleep apnea, in high-risk low-SES persons.
  • Analyze or test the impact of a multilevel intervention to improve rates of screening, referral, treatment, and control for hypertension and hypercholesterolemia, that addresses patient, provider, and system factors.
  • Analyze or test a community-partnered program to screen for and treat CVD risk factors such as hypertension in a novel setting by non-traditional providers that targets a population with low screening rates, such as Hispanic men.
  • Analyze or test a screening program for atrial fibrillation in an underserved rural population at high risk using new technology (e.g., wearable devices, phones).
  • Improve understanding of the basis for observed demographic differences in awareness and treatment of hypertension in NHLBI cohort study participants, such as the Jackson Heart Study, the Hispanic Community Health Study/Study of Latinos, and the Multi-Ethnic Study of Atherosclerosis.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Lawton S. Cooper, MD, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Email: cooperls@nhlbi.nih.gov
Telephone: 301-435-0419?

Nicole Redmond, MD, PhD, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Email: Nicole.Redmond@nih.gov
Telephone: 301-435-0379

Financial/Grants Management Contact(s)

Gayle Jones
National Heart, Lung, and Blood Institute (NHLBI)
Email: jonesgt@nhlbi.nih.gov

Telephone: 301-827-8040


Please direct all inquiries to:

Lawton Cooper, MD

National Heart, Lung, and Blood Institute (NHLBI)

Email: cooperls@nhlbi.nih.gov

Telephone: 301-435-0419